The acute effects of kava and oxazepam on anxiety, mood, neurocognition; And genetic correlates: A randomized, placebo-controlled, double-blind study

Human Psychopharmacology

Volumn 27, Issue 3, 2012, Pages 262-269

  Sarris, J ^a,b   Scholey, A ^b   Schweitzer, I ^a   Bousman, C ^a   LaPorte, E ^b   Ng, C ^a   Murray, G ^b   Stough, C ^b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

cognition; kava; oxazepam; pharmacogenetics; Piper methysticum; polymorphisms

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GAMMA GLUTAMYLTRANSFERASE; KAVA EXTRACT; OXAZEPAM; PLACEBO; SEROTONIN TRANSPORTER;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIDEPRESSANT ACTIVITY; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETICS; HEADACHE; HUMAN; MALE; MOOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; STATE TRAIT ANXIETY INVENTORY; TRANQUILIZING ACTIVITY;

ADOLESCENT; ADULT; AGED; ANTI-ANXIETY AGENTS; ANXIETY; COGNITION DISORDERS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAVA; LIVER; MALE; MIDDLE AGED; MOOD DISORDERS; NEUROPSYCHOLOGICAL TESTS; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; OXAZEPAM; PHYTOTHERAPY; PLANT PREPARATIONS; POLYMORPHISM, GENETIC; PSYCHIATRIC STATUS RATING SCALES; YOUNG ADULT;

EID: 84861184403     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2216     Document Type: Article

References (33)

1. Bond A, Lader M,. 1974. The use of analogue scales in rating subjective feelings. Br J Med Psychol 47: 211-218.
2. Buffet-Jerrott SE, Stewart SH, Teehan MD,. 1998. A further exmination of the time-dependent effects of oxazepam and lorazepam on implicit and explicit memory. Psychopharmacology 138: 344-353. (Pubitemid 28365500)
3. Foo H, Lemon J,. 1997. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev 16 (2): 147-155. (Pubitemid 127531298)
4. Greenblatt DJ, Koch-Weser J,. 1975. Clinical pharmacokinetics. N Engl J Med 293: 964-970.
5. Hamilton M,. 1959. The assessment of anxiety states by rating. Br J Med Psychol 32 (1): 50-55.
6. Heinze HJ, Münte TF, Steitz J, Matzke M,. 1994. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. Pharmacopsychiatry 27 (6): 224-230. (Pubitemid 24337137)
7. Herbert M, Standen J, Short AH, Birmingham AT,. 1983. A comparison of some psychological and physiological effects exerted by zetidoline (DL308) and by oxazepam. Psychopharmacology 81 (4): 335-339. (Pubitemid 14209489)
8. Horstmann S, Binder EB,. 2009. Pharmacogenomics of antidepressant drugs. Pharmacol Ther 124 (1): 57-73.
9. Kerr JS, Hindmarch I, Sherwood N,. 1992. Correlation between doses of oxazepam and their effects on performance of a standardised test battery. Eur J Clin Pharmacol 42 (5): 507-510.
10. Knight JA,. 2005. Liver function tests: their role in the diagnosis of hepatobiliary diseases. J Infus Nurs 28: 108-117. (Pubitemid 40393082)
11. LaPorte E, Sarris J, Stough C, Scholey A,. 2011. Neurocognitive effects of kava (Piper methysticum): a systematic review. Hum Psychopharmacol 26 (2): 102-111.
12. Münte TF, Heinze HJ, Matzke M, Steitz J,. 1993. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 27 (1): 46-53. (Pubitemid 23165779)
13. Pittler MH, Ernst E,. 2003. Kava extract for treating anxiety. Cochrane Database Syst Rev (1): CD003383.
14. Prescott J, Jamieson D, Emdur N, Duffield P,. 1993. Acute effects of kava on measures of cognitive performance, physiological function and mood. Drug Alcohol Rev 12 (1): 49-57.
15. Ruch W, Köhler G, van Thriel C,. 1996. Assessing the 'humorous temperament': construction of the facet and standard trait forms of the State-Trait-Cheerfulness-Inventory-STCI. Humor 9 (303-339).
16. Russell PN, Bakker D, Singh NN,. 1987. The effects of kava on altering and speed of access of information from long-term memory. B Psychonomic Soc 25 (4): 236-237.
17. Saletu B, Grunberger J, Linzmayer L, Anderer P,. 1989. EEG-Brain mapping, psychometric and psychophysiological studies on central effects of kavain-a kava plant derivative. Hum Psychopharmacol 4: 169-190. (Pubitemid 19211779)
18. Sarris J, Kavanagh D, Byrne G, Bone K, Adams J, Deed G,. 2009. The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled, cross-over trial using an aqueous extract of Piper methysticum. Psychopharmacology 205 (3): 399-407.
19. Sarris J, LaPorte E, Schweitzer I,. 2011a. Kava: a comprehensive review of efficacy, safety, and psychopharmacology. Aust N Z J Psychiatry 45 (1): 27-35.
20. Sarris J, Ng C, Schweitzer I,. 2011b. "Omic" genetic technologies for herbal medicines in psychiatry. Phytother Res. doi: 10.1002/ptr.3573
21. Sarris J, Teschke R, Stough C, Scholey A, Schweitzer, I,. 2010. Re-introduction of kava (Piper methysticum) to the EU: is there a way forward? Planta Med 77 (2): 107-10.
22. Scholey A, Ossoukhova A, Owen L, et al,. 2010. Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study. Psychopharmacology 212 (3): 345-356.
23. Schosser A, Kasper S,. 2009. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 24 (6): 277-288.
24. Sheehan DV, Lecrubier Y, Sheehan KH, et al,. 1998. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (20): 34-57.
25. Singh YN,. 1992. Kava: an overview. J Ethnopharmacol 37 (1): 13-45.
26. Singh YN, Singh NN,. 2002. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 16 (11): 731-743. (Pubitemid 35252722)
27. Spielberger CD,. 1985. Assessment of state and trait anxiety: conceptual and methodological issues. The Southern Psychologist 2: 6-16.
28. Teschke R, Sarris J, Lebot V,. 2010. Kava hepatotoxicity solution: a six-point plan for new kava standardization. Phytomedicine 15 (2-3): 96-103.
29. Thompson R, Ruch W, Hasenohrl RU,. 2004. Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (kava-kava). Hum Psychopharmacol 19 (4): 243-250. (Pubitemid 38868340)
30. Tiller JW, Schweitzer I,. 1992. Benzodiazepines. Depressants or antidepressants? Drugs 44 (2): 165-169.
31. Tiwari AK, Souza RP, Muller DJ,. 2009. Pharmacogenetics of anxiolytic drugs. J Neural Transm 116 (6): 667-677.
32. Weeks BS,. 2009. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. Med Sci Monit 15 (11): 256-262.
33. van Leeuwen TH, Verbaten MN, Koelega HS, Slangen JL, van der Gugten J, Camfferman G,. 1995. Effects of oxazepam on event-related brain potentials, EEG frequency bands, and vigilance performance. Psychopharmacology 122: 244-262.